Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2020

View Archived Issues

Metformin, explained

Autolus presents phase I data from Amelia study of AUTO-3 in pediatric patients

Phase I data presented for ambrisentan in sickle cell disease

PGC-1alpha as a novel therapeutic target in sickle cell disease

CD137 deficiency linked to susceptibility to EBV-associated lymphoma

Repotrectinib reduces tumor growth of ALK-driven neuroblastoma

Spot on: Breaching all three meninges improves drug delivery to brain

Ono presents phase II data for tirabrutinib in relapsed/refractory Waldenstrom's macroglobulinemia

Herantis advances xCDNF program into lead optimization

China NMPA approves Cecolin HPV16/18 vaccine

Amgen patents KRAS mutant inhibitors

New compounds for hepatitis B virus presented by VenatoRx Pharmaceuticals

Ryvu Therapeutics identifies hSTING receptor agonists

Pfizer divulges new GLP-1R agonists

Roche identifies new TLR7/8/9 antagonists

Regeneron begins open-label extension study with REGN-3918 in PNH

Genmab studies GEN-1042 safety for malignant solid tumors in phase I/IIa trial

Roche starts phase I study of RO-7296682 in advanced solid tumors

GSK initiates phase III study of belantamab mafodotin for newly diagnosed multiple myeloma

U.S. researchers present novel coagulation factor VIIa chimera for hemophilia patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...